Table 1. Combination therapies with... | American Society of Hematology

Table 1.

Combination therapies with venetoclax for patients with treatment-naive CLL

Regimen	Phase	n	ORR, %	CRR, %	MRD⁻ status, %	Median follow-up, mo	PFS	Median DOR	OS
VO¹⁷ (NCT01685892)	1b	32	100	78	91: 3 mo after last obinutuzumab 91: 9 mo after last obinutuzumab 78: 12 mo after last obinutuzumab	26.7	2 y = 90.6%	NR	NR
VO¹⁸	2	30	NA	NA	80 (24/29): end of obinutuzumab 86 (24/28): 6 mo after last obinutuzumab 89 (16/18): 9 mo after last obinutuzumab	NA	NA	NA	NA
VO¹⁹ (NCT02242942)	3	216	84.7	49.5	75.5: 3 mo after venetoclax	28.1	2 y = 88.2%	NR	2 y = 92%
Venetoclax + ibrutinib²⁶ (NCT02756897)	2	80	100*	96*	69: 18 mo of combination*	14.8	1 y = 98%	NR	1 y = 99%
Venetoclax + ibrutinib + obinutuzumab²⁷ (NCT02427451)	2	25	84†	32†	83: end of obinutuzumab 95: 2 mo after last obinutuzumab	24.2	NA	NA	NA

Regimen	Phase	n	ORR, %	CRR, %	MRD⁻ status, %	Median follow-up, mo	PFS	Median DOR	OS
VO¹⁷ (NCT01685892)	1b	32	100	78	91: 3 mo after last obinutuzumab 91: 9 mo after last obinutuzumab 78: 12 mo after last obinutuzumab	26.7	2 y = 90.6%	NR	NR
VO¹⁸	2	30	NA	NA	80 (24/29): end of obinutuzumab 86 (24/28): 6 mo after last obinutuzumab 89 (16/18): 9 mo after last obinutuzumab	NA	NA	NA	NA
VO¹⁹ (NCT02242942)	3	216	84.7	49.5	75.5: 3 mo after venetoclax	28.1	2 y = 88.2%	NR	2 y = 92%
Venetoclax + ibrutinib²⁶ (NCT02756897)	2	80	100*	96*	69: 18 mo of combination*	14.8	1 y = 98%	NR	1 y = 99%
Venetoclax + ibrutinib + obinutuzumab²⁷ (NCT02427451)	2	25	84†	32†	83: end of obinutuzumab 95: 2 mo after last obinutuzumab	24.2	NA	NA	NA

CRR, complete response rate; DOR, duration of response; NA, not available; NR, not reached.

Not reported by intention-to-treat population. As assessed in 26 available patients after 18 cycles of ibrutinib and venetoclax combination therapy.

As assessed by intention to treat.